# A Phase II Neoadjuvant Study of Darolutamide Plus ADT in Men With Localized Prostate Cancer

> **NCT06029036** · PHASE2 · RECRUITING · sponsor: **Peking University First Hospital** · enrollment: 53 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Darolutamide+ADT

## Key facts

- **NCT ID:** NCT06029036
- **Lead sponsor:** Peking University First Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-05
- **Primary completion:** 2025-07-31
- **Final completion:** 2026-07-31
- **Target enrollment:** 53 (ESTIMATED)
- **Last updated:** 2023-12-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06029036

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06029036, "A Phase II Neoadjuvant Study of Darolutamide Plus ADT in Men With Localized Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06029036. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*